These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 34902760)

  • 1. CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
    Baker D; MacDougall A; Kang AS; Schmierer K; Giovannoni G; Dobson R
    Mult Scler Relat Disord; 2022 Jan; 57():103448. PubMed ID: 34902760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
    Baker D; Pryce G; James LK; Marta M; Schmierer K
    Mult Scler Relat Disord; 2020 Sep; 44():102279. PubMed ID: 32645640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand'Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri D; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T
    Mult Scler; 2024 Aug; 30(9):1163-1175. PubMed ID: 39087208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.
    Brittain G; Petrie J; Duffy KEM; Glover R; Hullock K; Papaioannou D; Roldan E; Beecher C; Bursnall M; Ciccarelli O; Coles AJ; Cooper C; Giovannoni G; Gabriel I; Kazmi M; Kyriakou C; Nicholas R; Paling D; Peniket A; Scolding N; Silber E; de Silva T; Venneri A; Walters SJ; Young C; Muraro PA; Sharrack B; Snowden JA;
    BMJ Open; 2024 Feb; 14(2):e083582. PubMed ID: 38316583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
    Barun B; Gabelić T; Adamec I; Babić A; Lalić H; Batinić D; Krbot Skorić M; Habek M
    Mult Scler Relat Disord; 2021 Feb; 48():102704. PubMed ID: 33370649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both cladribine and alemtuzumab may effect MS via B-cell depletion.
    Baker D; Herrod SS; Alvarez-Gonzalez C; Zalewski L; Albor C; Schmierer K
    Neurol Neuroimmunol Neuroinflamm; 2017 Jul; 4(4):e360. PubMed ID: 28626781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
    Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
    J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
    Rodriguez-Mogeda C; van Lierop ZYGJ; van der Pol SMA; Coenen L; Hogenboom L; Kamermans A; Rodriguez E; van Horssen J; van Kempen ZLE; Uitdehaag BMJ; Teunissen CE; Witte ME; Killestein J; de Vries HE
    J Neuroinflammation; 2023 Sep; 20(1):215. PubMed ID: 37752582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.
    Gabelić T; Barun B; Adamec I; Krbot Skorić M; Habek M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4345-4362. PubMed ID: 34668842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab.
    Groß-Albenhausen E; Weier A; Velten M; Heider T; Chunder R; Kuerten S
    Front Immunol; 2023; 14():1254128. PubMed ID: 37841269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative safety of high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    Śladowska K; Kawalec P; Holko P; Osiecka O
    Neurol Sci; 2022 Sep; 43(9):5479-5500. PubMed ID: 35713731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab.
    Katz JD; Bouley AJ; Jungquist RM; Douglas EA; O'Shea IL; Lathi ES
    Mult Scler Relat Disord; 2022 Jan; 57():103382. PubMed ID: 35158475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab.
    Buttari F; Bruno A; Dolcetti E; Azzolini F; Bellantonio P; Centonze D; Fantozzi R
    Mult Scler Relat Disord; 2021 Jul; 52():102983. PubMed ID: 33990054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Immunological Impact of Ocrelizumab Extended Interval Dosing in Multiple Sclerosis: A Single-Center, Real-World Experience.
    Nasello M; Zancan V; Rinaldi V; Marrone A; Reniè R; Diamant S; Marconi M; Le Mura L; Salvetti M; Buscarinu MC; Bellucci G
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?
    Tazza F; Lapucci C; Cellerino M; Boffa G; Novi G; Poire I; Mancuso E; Bruschi N; Sbragia E; Laroni A; Capello E; Inglese M
    J Neurol Sci; 2021 Aug; 427():117501. PubMed ID: 34044238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients.
    Georgieva ZG; Dӧffinger R; Kumararatne D; Coles AJ; McCarthy C
    Mult Scler; 2022 Jun; 28(7):1126-1130. PubMed ID: 34595965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
    Adamec I; Habek M
    Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience.
    Guerrieri S; Bucca C; Nozzolillo A; Genchi A; Zanetta C; Cetta I; Rugarli G; Gattuso I; Azzimonti M; Rocca MA; Moiola L; Filippi M;
    Eur J Neurol; 2023 Sep; 30(9):2859-2864. PubMed ID: 37227923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.